How the COVID-19 pandemic has affected depression and anxiety around the world

October 8, 2021 | 20 views

A report in The Lancet provides the first global estimates of the impact of the COVID-19 pandemic on mental health in 2020, and suggests an additional 53 million cases of major depressive disorder and 76 million cases of anxiety disorders were due to the pandemic. Even before the COVID-19 pandemic, major depressive disorder and anxiety disorders – which can increase the risk of other health outcomes such as suicide – were major contributors to the global burden of disease, affecting millions of men and women of all ages around the world. This study is the first to assess global impacts of the pandemic on major depressive disorder and anxiety disorders, quantifying the prevalence and burden of the disorders by age, sex, and location in 204 countries and territories in 2020.

Spotlight

Medcor

Medcor provides clinical interventions and management services to help companies reduce their health-care costs and improve health outcomes. Medcor provides its services with staff and systems located on-site in large client locations or telephonically for smaller locations. Business entities can also integrate Medcor’s clinical interventions into their own systems to establish branded clinics.

OTHER ARTICLES
FUTURE OF HEALTHCARE

Wearable Technology: A Pool of Opportunities in Healthcare

Article | January 10, 2022

Introduction The field of smart wearable devices has advanced significantly in recent years as a result of the advent of mobile medicine, the development of new technologies like smart sensing, and the increased penetration of personalized health concepts. These Internet of Things (IoT)-based smart devices not only help people pursue a healthier lifestyle, but also offer a constant flow of healthcare data, which can be used for disease diagnosis and treatment, by actively recording, tracking, and monitoring metabolic status and physiological parameters. Wearable technologies have the potential to completely change the ways to monitor health behavior and are increasingly finding clinical implementation for patients with various types of diseases. Wearable Technology: New Ways of Patient Monitoring While wearable technology has demonstrated value in the fields of entertainment, fitness, and gaming, it is making inroads into the healthcare industry at a rapid pace. Increasing advancements in sensor technology and artificial intelligence (AI) are assisting millions of people in detecting and managing chronic health conditions and avoiding serious illnesses using devices that are as small as a patch the size of a penny or small enough to be worn on the wrist. According to a study, nearly 320 million consumer health and wellness wearable devices are estimated to be shipped across the globe in 2022, and the number is likely to surpass 440 million units as a number of new devices come out and more healthcare providers start using them. Most wearable devices, such as smartwatches, now include heart rate monitors, and some have FDA approval for detecting abnormalities such as atrial fibrillation, a major cause of stroke. As these devices become more intelligent, the percentage of patients and consumers who use them to manage chronic health conditions and diagnose symptoms of serious diseases is likely to rise. This is expected to assist the sales of wearable devices in healthcare to exceed $195 billion by the end of 2027, presenting huge prospects for healthcare equipment providers and associated companies to benefit from the opportunity. The Future of Wearable Technology in Healthcare Though wearable technology is experiencing rapid growth, the field is still considered to be in its nascent stage, presenting massive remunerative prospects for the manufacturers of smart devices, especially in the healthcare industry. Hence, companies of all kinds, from giants to upstarts, are emphasizing on investing and developing new wearable devices with new features and functionalities to meet the surging demand for wearables across healthcare in coming years.

Read More
FUTURE OF HEALTHCARE

The Long-Term Care Software: Mapping the Future

Article | December 8, 2020

Long-term care comprises all the health services that help patients with chronic illnesses or disabilities meet their medical and non-medical needs. It caters to those who cannot care for themselves for extended durations. For care providers, it becomes critical to meet the needs of patients on time while delivering top-notch quality, especially at a time when virtual care is more important than ever. To remedy this, many of the tasks and processes within long-term care are supported by digital solutions. These long-term care software applications enable care providers to automate aspects of patient scheduling, inventory control, regulation and compliance, data management, care delivery management, and much more. Some of the end users of long-term care software include home healthcare agencies, nursing homes, and residential hospice care facilities. What is Driving the Growth of Long-Term Care Solutions? Digitalization has swept the healthcare industry, and medical technology now occupies a significant area of medical care delivery. With the demand for a robust healthcare infrastructure aggravated by a shortage of medical professionals, the need for automation is driving the growth of medtech across all areas of healthcare. In addition, fewer medical specialists and medical cost reduction initiatives combined are powering the long-term care software market’s growth. Challenges for the Long-Term Care Software Market Despite the rapid growth in the use of digital solutions to manage administrative and compliance tasks, technological transformations are expensive. The high maintenance costs incurred by care providers are a major hindrance towards a full-fledged adoption. Many care providers are also unwilling to adopt new applications due to the implementation and staff training costs involved in doing so. What the Future Holds? With an increase in remote care and the use of technologies like the Internet of Medical Things to deliver diagnostic services and preventive care, medtech is witnessing a revolution. Long-term care is bound to follow suit thanks to areas like remote patient monitoring and wearable technology. While the long-term care market is slated to grow by leaps and bounds, solution makers must find a way to help care providers warm up to the use of technology and de

Read More
FUTURE OF HEALTHCARE

Amazon Care: Revolutionizing Virtual Care

Article | January 8, 2021

In 2021, the introduction of Amazon Care marked the first time a prominent technology firm stepped into the healthcare services industry. The fact that Amazon filed paperwork to offer care in multiple states without much fanfare is intriguing. In March 2021, the company confirmed the details of its new services, announcing that it would be delivering the services through an independent private medical practice called Care Medical. The move may signify another diversification for Amazon, but what does it mean for the healthcare services landscape? The Highlights of Amazon Care’s Services Home healthcare Amazon announced that it would be participating in an advocacy group for home healthcare. The Moving Health at Home initiative aims to transform how policymakers view the home as a site to deliver clinical services. Amazon Care may be riding on the trend for home care that has been evolving in the form of remote patient monitoring for post-acute care management and chronic care. Employer-oriented offering Amazon Care aims to become a workplace benefit partner for employers. One of the pain points it is directly addressing is the challenge of runaway inflation that increases healthcare costs. Virtual care simplified The most significant offering that Amazon Care plans to lead with is virtual care that promises to reduce wait times for quality patient care to under 60 seconds. It also includes the option to access 24-hour care services through messaging and video calling. In addition, it eliminates unnecessary traveling and long wait times by delivering care in the comfort of the patient’s home. The Path Ahead Amazon is known for introducing a slew of initiatives in the health and fitness sector, like the Halo wearables, a data management product called Amazon Health Lake, and a healthcare delivery system called Haven, which doubled over in 2021 after a three-year run. However, the tech juggernaut is not about to stop attempting to disrupt healthcare services. Only time will tell whether Amazon Care finally proves to be a feather in Amazon’s healthcare cap or another ambitious project that bites the dust.

Read More
HEALTH TECHNOLOGY

3 IT Investment Strategies Hospitals Can Use to Improve Patient Care

Article | July 5, 2022

Rural, community, and independent hospitals are constantly facing mounting challenges in the form of staff shortages, accessibility to patient care and a multitude of cost concerns. Getting even one of these areas under control can help hospitals drastically boost their outcomes. Here are three areas of IT investment that hospitals must control to go beyond staying functional and create an excellent patient experience. Telehealth for Staff Shortage Healthcare currently face massive staff shortage with a projected gap of up to 48,000 primary care physicians and up to 77,100 specialty physicians till 2034. The effects of this shortage could be lessened by using virtual care, which would allow hospitals to care for patients through remote staffing. Digitalizing Patient Care with Asynchronous Telehealth Async telehealth of patients sending photos and videos to fast-track diagnosis. Async telehealth makes it easier for doctors to connect with more patients. This shortens the time it takes to see specialists and get important care services. Remote Patient Monitoring According to a CDC report, 90% of all healthcare spending goes into treating chronic conditions. Considering that U.S. nonmetropolitan areas have a high number of patients diagnosed with chronic conditions, accessibility is one of the contributing factors. Remote patient monitoring enhances patient care for people with chronic conditions. Wearable medical devices are already driving the move towards remote patient monitoring. Whether it’s through wearable weight scales, heart monitors, blood pressure bands, or pulse oximeters, clinicians can generate regular updates about a patient’s health readings and ensure a timely response in order to avert complications. Conclusion There is much to be achieved on the healthcare front when it comes to digitalizing care. The above technologies are enabling healthcare providers take delivery of medical care further than ever and ensure they generate more traction from their IT investments in these areas of medtech.

Read More

Spotlight

Medcor

Medcor provides clinical interventions and management services to help companies reduce their health-care costs and improve health outcomes. Medcor provides its services with staff and systems located on-site in large client locations or telephonically for smaller locations. Business entities can also integrate Medcor’s clinical interventions into their own systems to establish branded clinics.

Related News

HEALTH TECHNOLOGY

IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation

IQVIA | September 29, 2022

IQVIA a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry announced its Decentralized Clinical Trial (DCT) program has received GDPR compliance validation from TRUSTArc. This marks the first instance of a DCT service receiving this European data privacy validation. TRUSTArc’s third-party validation demonstrates that IQVIA’s DCT program processes personal data in accordance with GDPR, allowing customers to address participant and investigator privacy concerns that may arise because of their participation in decentralized trials. “At IQVIA, we are committed to delivering decentralized studies, we recognize the criticality of patient data protection in doing this and we understand the focus on data protection by European regulators,” said Ronan Brown, SVP and head of Patient Centric Solutions & Decentralized Trials. “IQVIA is proud to have this validation prove our longstanding dedication to data protection in decentralized trials.” TRUSTArc maps it’s GDPR Validation requirements to applicable GDPR Articles and ISO 27001 standards, alongside the standards of it’s own Privacy and Data Governance Accountability Framework. This validation is yet another step IQVIA has taken to enable DCTs to be brought to a wider group of participants, improving diversity, sustainability, and trust in clinical development. “Achieving a GDPR validation demonstrates IQVIA’s commitment to ensuring the highest standards of delivering decentralized studies to the people it serves. Organizations of all sizes must become privacy-forward to earn the trust of their customers. IQVIA has consistently prioritized being privacy-forward to earn the trust of their customers and the TRUSTArc GDPR and CCPA Validations reinforce that standing.” Chris Babel, CEO, TRUSTArc About IQVIA IQVIA is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 82,000 employees, IQVIA conducts operations in more than 100 countries. IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors, and scientific advances, in an effort to advance their path toward cures.

Read More

HEALTH TECHNOLOGY

Aktana Welcomes New Medical Affairs Lead from IBM Watson Health (Now Merative)

Aktana | September 28, 2022

Aktana, the leader in intelligent customer engagement for the global life sciences industry, welcomes Deepak Patil as its new senior director of medical strategy. Patil comes to Aktana after leadership roles at IBM Watson Health, IQVIA, and Sun Pharma Industries where he managed medical affairs in conjunction with six key product launches and developed lasting relationships with key opinion leaders in targeted therapeutic areas. At Aktana, Patil will lead the company’s medical affairs program, initially helping to build modern, data-driven solutions for medical science liaisons but over time, also expand to other areas within medical affairs. Medical Affairs is the “third strategic pillar of the pharmaceutical organization alongside R&D and commercial, as science and data merge,” according to a McKinsey report. Business models are starting to evolve both around and beyond the “product” to encompass the wider therapeutic context, while organizations seek to explain and contextualize the ever more complex medical science to a diverse range of stakeholders. In outreach efforts, MSLs and commercial teams can unintentionally overlap, causing major compliance issues and frustrating doctors. Aktana’s intelligence solutions will not only help medical affairs improve key opinion leader relationships but also better orchestrate outreach to the physician community in compliance with regional engagement regulations. “Deepak brings a unique blend of medical experience – he received his medical degree in India – plus data science and operational expertise from IQVIA and IBM. As we prioritize new, AI-driven solutions for medical affairs teams, Deepak will help expertly shape our new offerings while building a powerhouse team focused on this increasingly important area of life sciences.” Clay Hausmann, chief revenue officer at Aktana Aktana has also announced a strategic partnership with Envision Pharma Group, a global, technology-enabled scientific communications company operating across many areas of medical affairs. Envision and Aktana will combine their offerings to help MSLs address HCP demands for personalized scientific content and coordinated omnichannel engagement. “Aktana is committed to enabling the medical affairs organization in a new era, and I’m excited to serve in a leadership role as part of this endeavor,” said Deepak Patil. “The real-world data is there. With the right technology, we have the power to improve the generation and dissemination of scientific insights to physicians, leading to better treatment decisions and outcomes for their patients.” With more than 300 deployments across 50+ use cases, Aktana has been refining its commercial life sciences intelligence platform for more than a decade. More than half of the world's top-20 pharmaceutical companies rely on Aktana to coordinate and optimize personalized omnichannel engagement with HCPs. Aktana’s Contextual Intelligence 360 platform is powered by the company’s next-generation Contextual Intelligence Engine, which uses AI-driven optimization to predict the value of all potential customer experiences, then prioritize and recommend Next Best Engagements that will deliver the highest ROI. About Aktana Aktana is the category creator and leader of intelligent engagement in the global life sciences industry. By ensuring that every customer experience is tailored to individual preferences and needs, Aktana helps life science companies strengthen their relationships with healthcare providers to inspire better patient care. Today, commercial and medical teams from more than 300 brands use Aktana’s AI-enabled Contextual Intelligence Engine to coordinate and optimize personalized omnichannel engagement at scale. More than half of the top-20 global pharmaceutical companies are Aktana customers. Headquartered in San Francisco, Aktana has offices in every major biopharma region around the world.

Read More

FUTURE OF HEALTHCARE

Brain Navi Biotechnology Announced Partnership with Distributor, Medtreq Medical Equipment

Brain Navi Biotechnology Co., Ltd. | September 12, 2022

Brain Navi, the leading surgical robot manufacture in Taiwan, announced a strategic partnership with distributor, Medtreq Medical Equipment, to expand the distribution of the Surgical Navigation Robot, NaoTrac, throughout the region of GCC region, Jordan, Egypt plus other countries in the Middle East and Philippines, Indonesia, Malaysia, and Singapore which will be covered by Medtreq branch in Philippines. NaoTrac, a CE-certified and local government approval neurosurgical navigation robot from Brain Navi Biotechnology, is embedding dissimilar technology named SMART Technology which combining the machine vision and in-house algorithm to perform robot-assisted surgery, to streamline surgical procedures with real-time imaging and minimal invasive outcomes. "We are always scouting for the new technology to help as many people as we can. We have many neurosurgeons coming from Riyadh and some other territories keening and willing to learn more about this technology, and the NaoTrac from Brain Navi is one of them. We are always happy to partner with an innovative technology company," Sherif Bayoumy, the General Manager of Medtreq Medical Equipment The collaboration and partnership between Brain Navi and Medtreq enables greater innovative outcome in the Middle East neurosurgery, such as Saudi Arabia, UAE, Egypt, Jordan, and some of the other countries on progressing, to streamline the surgical procedure, improve the surgical accuracy and pass-on knowledge to shorten the learning curves. "We seek strategic partners that can accelerate Brain Navi's growth mission. This partnership is a significant step toward scaling our business and getting more robot-assisted neurosurgery into the world," said Jerry Chen, the CEO of Brian Navi Biotechnology. "The collaboration between Metreq and Brain Navi is looking positive because we share the same mission to innovate with technology to make the life bright. We truly believe that the collaboration between Brain Navi and Medtreq can maximum the value of both sides to bring the neurosurgery to the next level." About Metreq Medical Equipment Bahrain Medtreq Medical Equipment provides professional technical support and after-service to clients in the MENA region with a presence in Bahrain and GCC, Egypt, North Africa, Turkey, Europe, the United States (Medtreq Tenessee USA), and the Philippines, Singapore, Malaysia, and Indonesia. Medtreq is built on high values, principles, and social commitment to society and humanity. About Brain Navi Brain Navi Biotechnology is a leading Taiwanese surgical robotic company. We design and develop innovative navigation and robotic surgery technologies for surgeons to improve surgical accuracy. Brain Navi's exclusive Surface Mapping Auto-registration Technology (SMART) is a significant surgical robotic breakthrough that merges machine vision, robotics, and AI technology to achieve streamlined surgical procedures with real-time imaging and minimal invasive outcomes.

Read More

HEALTH TECHNOLOGY

IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation

IQVIA | September 29, 2022

IQVIA a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry announced its Decentralized Clinical Trial (DCT) program has received GDPR compliance validation from TRUSTArc. This marks the first instance of a DCT service receiving this European data privacy validation. TRUSTArc’s third-party validation demonstrates that IQVIA’s DCT program processes personal data in accordance with GDPR, allowing customers to address participant and investigator privacy concerns that may arise because of their participation in decentralized trials. “At IQVIA, we are committed to delivering decentralized studies, we recognize the criticality of patient data protection in doing this and we understand the focus on data protection by European regulators,” said Ronan Brown, SVP and head of Patient Centric Solutions & Decentralized Trials. “IQVIA is proud to have this validation prove our longstanding dedication to data protection in decentralized trials.” TRUSTArc maps it’s GDPR Validation requirements to applicable GDPR Articles and ISO 27001 standards, alongside the standards of it’s own Privacy and Data Governance Accountability Framework. This validation is yet another step IQVIA has taken to enable DCTs to be brought to a wider group of participants, improving diversity, sustainability, and trust in clinical development. “Achieving a GDPR validation demonstrates IQVIA’s commitment to ensuring the highest standards of delivering decentralized studies to the people it serves. Organizations of all sizes must become privacy-forward to earn the trust of their customers. IQVIA has consistently prioritized being privacy-forward to earn the trust of their customers and the TRUSTArc GDPR and CCPA Validations reinforce that standing.” Chris Babel, CEO, TRUSTArc About IQVIA IQVIA is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 82,000 employees, IQVIA conducts operations in more than 100 countries. IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors, and scientific advances, in an effort to advance their path toward cures.

Read More

HEALTH TECHNOLOGY

Aktana Welcomes New Medical Affairs Lead from IBM Watson Health (Now Merative)

Aktana | September 28, 2022

Aktana, the leader in intelligent customer engagement for the global life sciences industry, welcomes Deepak Patil as its new senior director of medical strategy. Patil comes to Aktana after leadership roles at IBM Watson Health, IQVIA, and Sun Pharma Industries where he managed medical affairs in conjunction with six key product launches and developed lasting relationships with key opinion leaders in targeted therapeutic areas. At Aktana, Patil will lead the company’s medical affairs program, initially helping to build modern, data-driven solutions for medical science liaisons but over time, also expand to other areas within medical affairs. Medical Affairs is the “third strategic pillar of the pharmaceutical organization alongside R&D and commercial, as science and data merge,” according to a McKinsey report. Business models are starting to evolve both around and beyond the “product” to encompass the wider therapeutic context, while organizations seek to explain and contextualize the ever more complex medical science to a diverse range of stakeholders. In outreach efforts, MSLs and commercial teams can unintentionally overlap, causing major compliance issues and frustrating doctors. Aktana’s intelligence solutions will not only help medical affairs improve key opinion leader relationships but also better orchestrate outreach to the physician community in compliance with regional engagement regulations. “Deepak brings a unique blend of medical experience – he received his medical degree in India – plus data science and operational expertise from IQVIA and IBM. As we prioritize new, AI-driven solutions for medical affairs teams, Deepak will help expertly shape our new offerings while building a powerhouse team focused on this increasingly important area of life sciences.” Clay Hausmann, chief revenue officer at Aktana Aktana has also announced a strategic partnership with Envision Pharma Group, a global, technology-enabled scientific communications company operating across many areas of medical affairs. Envision and Aktana will combine their offerings to help MSLs address HCP demands for personalized scientific content and coordinated omnichannel engagement. “Aktana is committed to enabling the medical affairs organization in a new era, and I’m excited to serve in a leadership role as part of this endeavor,” said Deepak Patil. “The real-world data is there. With the right technology, we have the power to improve the generation and dissemination of scientific insights to physicians, leading to better treatment decisions and outcomes for their patients.” With more than 300 deployments across 50+ use cases, Aktana has been refining its commercial life sciences intelligence platform for more than a decade. More than half of the world's top-20 pharmaceutical companies rely on Aktana to coordinate and optimize personalized omnichannel engagement with HCPs. Aktana’s Contextual Intelligence 360 platform is powered by the company’s next-generation Contextual Intelligence Engine, which uses AI-driven optimization to predict the value of all potential customer experiences, then prioritize and recommend Next Best Engagements that will deliver the highest ROI. About Aktana Aktana is the category creator and leader of intelligent engagement in the global life sciences industry. By ensuring that every customer experience is tailored to individual preferences and needs, Aktana helps life science companies strengthen their relationships with healthcare providers to inspire better patient care. Today, commercial and medical teams from more than 300 brands use Aktana’s AI-enabled Contextual Intelligence Engine to coordinate and optimize personalized omnichannel engagement at scale. More than half of the top-20 global pharmaceutical companies are Aktana customers. Headquartered in San Francisco, Aktana has offices in every major biopharma region around the world.

Read More

FUTURE OF HEALTHCARE

Brain Navi Biotechnology Announced Partnership with Distributor, Medtreq Medical Equipment

Brain Navi Biotechnology Co., Ltd. | September 12, 2022

Brain Navi, the leading surgical robot manufacture in Taiwan, announced a strategic partnership with distributor, Medtreq Medical Equipment, to expand the distribution of the Surgical Navigation Robot, NaoTrac, throughout the region of GCC region, Jordan, Egypt plus other countries in the Middle East and Philippines, Indonesia, Malaysia, and Singapore which will be covered by Medtreq branch in Philippines. NaoTrac, a CE-certified and local government approval neurosurgical navigation robot from Brain Navi Biotechnology, is embedding dissimilar technology named SMART Technology which combining the machine vision and in-house algorithm to perform robot-assisted surgery, to streamline surgical procedures with real-time imaging and minimal invasive outcomes. "We are always scouting for the new technology to help as many people as we can. We have many neurosurgeons coming from Riyadh and some other territories keening and willing to learn more about this technology, and the NaoTrac from Brain Navi is one of them. We are always happy to partner with an innovative technology company," Sherif Bayoumy, the General Manager of Medtreq Medical Equipment The collaboration and partnership between Brain Navi and Medtreq enables greater innovative outcome in the Middle East neurosurgery, such as Saudi Arabia, UAE, Egypt, Jordan, and some of the other countries on progressing, to streamline the surgical procedure, improve the surgical accuracy and pass-on knowledge to shorten the learning curves. "We seek strategic partners that can accelerate Brain Navi's growth mission. This partnership is a significant step toward scaling our business and getting more robot-assisted neurosurgery into the world," said Jerry Chen, the CEO of Brian Navi Biotechnology. "The collaboration between Metreq and Brain Navi is looking positive because we share the same mission to innovate with technology to make the life bright. We truly believe that the collaboration between Brain Navi and Medtreq can maximum the value of both sides to bring the neurosurgery to the next level." About Metreq Medical Equipment Bahrain Medtreq Medical Equipment provides professional technical support and after-service to clients in the MENA region with a presence in Bahrain and GCC, Egypt, North Africa, Turkey, Europe, the United States (Medtreq Tenessee USA), and the Philippines, Singapore, Malaysia, and Indonesia. Medtreq is built on high values, principles, and social commitment to society and humanity. About Brain Navi Brain Navi Biotechnology is a leading Taiwanese surgical robotic company. We design and develop innovative navigation and robotic surgery technologies for surgeons to improve surgical accuracy. Brain Navi's exclusive Surface Mapping Auto-registration Technology (SMART) is a significant surgical robotic breakthrough that merges machine vision, robotics, and AI technology to achieve streamlined surgical procedures with real-time imaging and minimal invasive outcomes.

Read More

Events